HRAS G12V transformation effect on MCF-10A cells harboring different p53 variants by نور الدين يوسف موسى طردي & Nooraldeen Yousef Mousa Tarade
 
 
 Deanship of Graduate Studies 
Al-Quds University 
 
 
 
 
 
 
 
HRAS G12V transformation effect on MCF10A cells 
harboring different p53 variants 
 
 
 
Nooraldeen Yousef Mousa Tarade 
 
 
 
 
Master’s Thesis 
 
 
Jerusalem – Palestine 
 
 
 
 
2019 /1440  
 
 
HRAS G12V transformation effect on MCF-10A cells 
harboring different p53 variants 
 
 
 
 
 
 
Prepared by: 
Nooraldeen Yousef Mousa Tarade 
 
 
 
 
B.Sc. Medical Technology, Al-Quds University-Palestine 
 
 
 
 
Supervisor: Dr. Zaidoun Salah  
 
 
A thesis Submitted in Partial fulfillment of requirement for 
the degree of Master of Biochemistry and Molecular 
Biology, Faculty of Medicine -Al-Quds University.  
 
 
 
2019 /1440  

 
 
Dedication 
  
To my mother and father... 
To my brothers and sisters... 
To my friends... 
To all beloved people who supported, assisted and encouraged me. 
   
 
 
 
Nooraldeen Yousef Mousa Tarade 

II 
 
Acknowledgements 
 
First of all, I would like to thank Allah for giving me strength to continue this work. I would like to give 
my gratitude and appreciation to those who contributed and made this research possible. 
 
I would like to reserve my deepest gratitude, appreciation and respect to my supervisor Dr. Zaidoun Salah 
for his eagerness, inspiration and countless efforts to patiently refine and clarify concepts to me throughout 
the research process. I am grateful for him not only giving me the opportunity to join his research project 
and providing me the freedom to work independently, but also guiding me on the correct path when needed. 
Also, I want to thank him for his patience throughout my writing process, as his editing recommendations 
were critical in producing the final draft. 
 
I would like to express my appreciation to Prof. Dr. Stefan Wiemann for both accepting me and giving me 
a great opportunity to complete part of my master thesis research in the Molecular Genome Analysis 
Division at the German Cancer Research Center (DKFZ). In addition to this, his continued support and 
encouragement during my research stay was invaluable and greatly appreciated. I would also like to thank 
all the members of DKFZ’s Molecular Genome Analysis Department: Dr. Cindy Körner, Dr. Rainer Will, 
Dr. Khaled Abnaof, Heike Wilhelm, Angelika Wörner, Daniela Fischer, Xiaoya Li, Emre Sofyali, Nese 
Erdem and Dámaris Intriago. Throughout my research stay, their varied and continuous offers of help and 
support are not forgotten. 
 
My appreciation is also extended to my friend Yosef Torman for his assistance and constructive comments 
in the lab. He always offered to help and gave key perspective to help during my research. I would also like 
to express my deeply felt gratefulness to Al-Quds University’s Biochemistry and Molecular Biology 
program in the Faculty of Medicine. Their support was seen and represented by all the teachers and 
colleagues. I am deeply thankful to Dr. Suheir Ereqat, Dr. Imad Matouq, Dr. Kifaya Azmi, and Dr. Rula 
Abdul-Ghani. I also would like to express my sincerest gratitude to Dr. Dina Bitar; I am forever indebted 
to her priceless guidance and advice during my work under her supervision in the Faculty of Medicine.   
 
Last but not least, I would like to thank Dr. Sameer Barghouthi, Dr. Elham Kateeb, Dr. Hatem Eideh, Dr. 
Ahmad Amro, Dr. Murad Ibrahim, Ms. Wajd Qassas and Mrs. Asma Bader for all their support and valuable 
advice. Also, my appreciation is extended to Mr. Mahmoud Zahayka for his help and support in the lab. 
III 
 
Table of contents 
 
Dedication ................................................................................................................................ IV 
Declaration.................................................................................................................................. I 
Acknowledgements .................................................................................................................... II 
List of abbreviations ................................................................................................................... V 
Abstract .................................................................................................................................. VII 
List of tables .......................................................................................................................... VIII 
List of figures ......................................................................................................................... VIII 
1. Introduction .........................................................................................................................1 
1.1. Cancer transformation ...................................................................................................1 
1.2. Breast Cancer ................................................................................................................2 
1.3. The Oncogen-RAS ........................................................................................................3 
1.4. The tumor suppresser- p53 ............................................................................................5 
1.5. HRAS G12V and TP53 variants combination role in cancer transformation ...................9 
1.6. Problem statement and motivation of the study ........................................................... 10 
1.7. Hypothesis .................................................................................................................. 11 
1.8. Aims of study ................................................................................................................. 11 
2. Materials and Methods ....................................................................................................... 12 
2.1. Materials ..................................................................................................................... 12 
2.2. Methods ...................................................................................................................... 15 
2.2.1. Cell culture .......................................................................................................... 15 
2.2.2. Cells cryopreservation .......................................................................................... 16 
2.2.3. Generation of stable cell lines pools ..................................................................... 16 
2.2.4. Selection .............................................................................................................. 17 
2.2.5. Cell count using fluorescent microscope .............................................................. 17 
2.2.6. Cell count using Neubauer counting chamber....................................................... 17 
2.2.7. XTT test............................................................................................................... 18 
2.2.8. Wound healing assay ........................................................................................... 18 
2.2.9. Survival assay ...................................................................................................... 18 
2.2.10. Anchorage-independent growth assay .................................................................. 18 
2.2.11. Soft agar assay ..................................................................................................... 18 
2.2.12. Matrigel 3D culture assay .................................................................................... 19 
IV 
 
2.2.13. RNA Extraction ................................................................................................... 19 
2.2.14. cDNA synthesis ................................................................................................... 20 
2.2.15. Real time PCR ..................................................................................................... 20 
2.2.16. Western blot......................................................................................................... 20 
2.2.17. Primer design ....................................................................................................... 21 
3. Results ............................................................................................................................... 22 
3.1. Generation of HRAS G12V MCF10A clones harboring different TP53 variants ........... 22 
3.2. Phenotypic change characterization of HRAS transduced MCF10A cells ..................... 23 
3.2.1.1. Effect of HRAS overexpression in combination of different TP53 variants on 
MCF10A cell proliferation ................................................................................................. 23 
3.2.2. HRAS overexpression and TP53 variants effects on MCF10A cell migration........ 27 
3.2.3. Effect of HRAS overexpression on cell survival of different MCF10A TP53 clones 
………………………………………………………………………………………………28 
3.2.4. HRAS overexpression and TP53 variants effect on MCF10A anchorage-
independent growth ............................................................................................................ 29 
3.2.5. Effect of HRAS overexpression in transduced MCF10A with different TP53 
variants on encourage cell tumorigenicity........................................................................... 30 
3.2.6. Effect of HRAS overexpression on the expression of genes related to different 
cancer phenotypes in cells harboring different TP53 variants ............................................. 34 
4. Discussion.......................................................................................................................... 37 
5. Conclusion and future outlook ........................................................................................... 42 
References ................................................................................................................................ 43 
صخلملا ....................................................................................................................................... 52 
 
 
 
 
 
 
 
 
 
 
 
 
V 
 
List of abbreviations 
 
°C Degree Celsius 
Bax Bacl-2 associated X protein   
BCL-2 B-cell lymphoma 2 
cDNA Complementary DNA 
cm centimeter 
CGS Cancer related Gene Signature 
COSMIC Catalogue of somatic mutations in cancer 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
EGF Epidermal growth factor 
EMT Epithelial mesenchymal transition 
EMC Extracellular matrix 
ER Estrogen receptor  
ERBB2 v-erb-b2 avian erythroblastic leukemia oncogene 
homolog 2 
G gram 
H hours 
HER2 Human epidermal receptor 2 
KO Knockout 
kDa Kilodalton 
L liter 
M Molar 
MDM2 Mouse double minute 2 homolog 
VI 
 
mg Milligram 
min Minute 
mL Milliliter  
mRNA Messenger RNA 
Ng Nanogram 
nm Nanometer 
nM Nanomolar 
Nt Nucleotide  
PBS Phosphate buffered saline 
PCR Polymerase chain reaction  
PI3K Phosphoinositide 3-kinase 
rpm Round per minute 
Rb Retinoblastoma 
RNA Ribonucleic acid 
SFM Serum free media  
Sec Second  
TCGA The cancer genome atlas 
TP53 Tumor protein 53  
U Units 
Wt Wilde-type 
Wtres Wild-type rescue  
µL Microliter  
µM Micromolar 
 
VII 
 
Abstract  
 
Breast cancer is the most frequent cancer type between women, which influences more than 2 
million women every year. It represents 15% of total cancer deaths among women. Genomic 
alternations are the main cause of breast cancer transformation. The differences in gene expression 
patterns among breast cancer subtypes are likely to reflect basic differences in the cell biology of 
each type and that gives the apparent phenotypes. The imbalance between the activities of tumor 
suppressors and oncogenes is a common event that leads to cancer transformation. Our preliminary 
data shows that different p53 variants lead to differential gene expression. Thus we hypothesized 
that different gene alteration combinations would result in differential gene expression pattern and 
consequently to different phenotypes. We aimed to create different breast cancer transformation 
models by transforming the normal mammary epithelial cell lines, MCF10A cells, that contain 
different TP53 gene variants with HRAS G12V. Afterwards, we tested the differences in distinct 
cellular phenotypes (cancer hallmarks) caused by this combination. The HRAS overexpression 
increased cell proliferation, migration, invasion and resistance to apoptosis. Moreover, HRAS 
overexpression in combination with different TP53 mutations lead to different phenotypes and 
gene expression patterns. This study demonstrates a critical role of two hit system in induction of 
cancer transformation.  Altogether, we successfully generated models for studying breast cancer 
transformation that might help in understanding the differential behavior of different breast cancer 
tumors, which could be used to improve breast cancer detection, diagnosis and treatment.  
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Chapter 1 
 
  
1. Introduction  
 
1.1. Cancer transformation  
 
Cancer is a genetic disease. Cancer cells are an out of controlled growth cells resulting from 
genetic mutations and epigenetic alternations, cellular signaling and hemostasis 
misregulation (Hanahan & Weinberg, 2011). Frequent pathological genetic changes could 
modify the actions of oncogenes and tumor suppressor genes. The oncogenes are group of 
genes that promote carcinogenesis. They result from abnormal activation of normal proto-
oncogenes like RAS and Her2 (Reuter, Morgan, & Bergmann, 2000; Spandidos, 1985). 
Tumor suppressor genes are a set of genes involved in inhibiting cell growth and cancer 
development like TP53 and Rb (Imran et al., 2017). Both activation of oncogenes and 
inactivation of tumor suppressor genes, abrogates cell hemostasis and induces different 
mutations. The accumulation of mutations forces normal cell to transform into cancer cell 
in a multistep process called cancer transformation by altering various pathways till tumor 
formation takes place (Johnson, Warmoes, Shen, & Locasale, 2015; Northcott et al., 2014).  
Different genetic alternations affect driver pathways during the multistep transformation 
process. Consequently, different cancer cell hallmarks result (Figure 1.1). These hallmarks 
include; continuous proliferation, resistance to apoptosis, evading tumor suppressors, 
immortality, enhanced angiogenesis, invasion and metastasis, inflammation, metabolism 
changes and immune evasion (Hanahan & Weinberg, 2011). 
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Figure 1.1: Cancer hallmarks. The hallmarks of cancer as described by Hanahan and 
Weinberg (modified from (Hanahan & Weinberg, 2011)). 
 
1.2. Breast Cancer  
 
Breast cancer is recognized as the most frequent cancer type among women, which 
influences more than 2 million women every year. It is the most cause of mortality among 
women worldwide. In 2018 627,000 women died from breast cancer worldwide, which 
makes up to nearly 15% of total cancer deaths among women (WHO, 2018). Breast cancer 
is a very heterogeneous cancer type and can be classified into different categorizes 
depending on different parameters. Based on clinical features, breast cancer is divided into 
3 groups: triple negative breast cancer (TNBC), estrogen receptor positive (ER+), and 
ERBB2-enriched (Cancer Genome Atlas, 2012).  
The majority of molecular findings of breast cancer studies have concentrated on one or two 
genetic profiles. Most common are mRNA expression or DNA copy number analysis, and 
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more recently enormously deep sequencing. Directed data of mRNA expression clustering 
has consistently established that breast cancer includes several different disease entities, 
often mentioned as the built-in subtypes of breast cancer. The current development of 
supplementary high information content assays concentrated on aberrations in microRNA 
expression, DNA methylation and protein expression(Ciriello et al., 2015).Based on gene 
expression profiles, breast cancer is categorized into 4 main subgroups: luminal A, luminal 
B, HER2-enriched and basal-like (Wang, Liu, Ying, Lin, & Zhou, 2016). 
The differences in gene expression patterns among breast cancer subtypes are likely to 
reflect basic differences in the cell biology of  each type and that gives the apparent 
phenotypes (Sorlie et al., 2003).  
 
1.3. The Oncogen-RAS 
 
RAS family of proteins belongs to GTPases, which have the ability to switch between the inactive 
GDP-bound form and the active GTP-bound form. This conversion is controlled by guanine 
nucleotide exchange factors (GEFs)(Karnoub & Weinberg, 2008).  
There are 3 isoforms of RAS including KRAS, HRAS and NRAS. They are very similar in their 
structure with 85% of amino acids sequence similarity and in their function (Downward, 2003). 
Active RAS proteins activate different signaling pathways that regulate different cellular 
functions, such as cellular growth, differentiation, proliferation and others (Figure 1.2) (Karnoub 
& Weinberg, 2008; Myers et al., 2016; Reuter et al., 2000). Furthermore, RAS pathway is from 
the highest frequent altered pathway in cancer (Maertens & Cichowski, 2014). It was established 
that 30 % of cancers harbor a somatic mutation in one of RAS superfamily (Prior, Lewis, & 
Mattos, 2012). These oncogenic mutated RAS proteins become unresponsive to GTPase-
activating proteins (GAPs) and constitutively active. Furthermore, RAS mutations were found in 
high percentage in different type of cancer such as pancreas, lung, colorectal and others ranging from 
30% to 90% (Downward, 2003). 
HRAS mutations are common among cancer patients in salivary gland 15%, urinary tract 
11%, cervical cancers 9% upper and aerodigestive tract 9%. According to the COSMIC 
database, mutations in HRAS is (~1%) in breast cancer (Myers et al., 2016). Nevertheless, 
low frequent measurement of RAS subfamily individuals in breast cancer is still of 
attention because they play a critical role in breast signaling pathways involving P13K 
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and MAPK pathways (Myers et al., 2016). The most common frequent HRAS somatic 
point mutations take place in codons 12, 13, 61 and 146 and lead to the constitutively active 
RAS (Fernandez-Medarde & Santos, 2011; Myers et al., 2016).G12V is a hotspot 
mutation arises from a single nucleotide replacement (c.35 G>T) that results in the 
exchange from Glycine (G) to Valine (V) and dominates in HRAS (57%) (Hobbs, Der, & 
Rossman, 2016). HRAS G12V is located at position 12 of the GTP nucleotide binding 
domain of HRAS protein. This mutation leads to the reduction of GTPase activity of 
HRAS protein, loss GAPs binding sensitivity and continuous HRAS activation. 
Altogether, these events induce cell transformation (Figueiredo, Stein, Jochem, & 
Sandgren, 2012; Hobbs et al., 2016).   
Several studies have described mutant HRAS G12V ability and role in transforming normal 
cells to cancer cells in vitro and in vivo. A study has shown that the combination between 
HRAS G12V and Ink4a/Arf−/−, a tumor suppressor locus, in mammary cells causes cancer 
transformation and 100% tumorigenesis when injected into syngeneic mice mammary fat 
pads. The resulting tumors were triple negative (Kai et al., 2014). Likewise, another in vitro 
study described that MCF10A cell lines harboring HRAS overexpression alone or with 
mutant P13KA or TP53 wild-type shows high oncogenic features(Geyer et al., 2018).  
In a further study, MCF10A cell lines with HRAS G12V and LBX1 were transformed to 
cancer cells. They expressed mesenchymal markers and developed tumors when injected 
into nude mice (Yu et al., 2009). Moreover, MCF10A cell lines containing HRAS G12V co-
expressed with Bim-1 show high epithelial to mesenchymal transition ability and form tumor 
masses when injected into mammary fat pad mice(Datta et al., 2007).   
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Figure 1.2: The activation (GTP-bound) and inactivation (GDP-bound) 
cycle of RAS protein in response to extracellular signals (Reuter et al., 
2000). 
 
1.4. The tumor suppresser- p53  
 
 TP53 gene is positioned on the short arm of 17p13.1 chromosome and encodes p53 protein 
(Matlashewski et al., 1984). p53 was named back to 1979 after its molecular weight which 
is 53 kailo dalton (kDa)(Ziemer, Mason, & Carlson, 1982).  
p53 is recognized as a transcription factor and a multifunctional protein that regulates 
different cellular mechanisms including apoptosis, oncogenes expression deregulation, cell 
cycle and DNA repair (Ford, 2005; T. Li et al., 2012). p53 critical role in the cell comes 
from its function as a transcription factor that controls more than 100 genes in the cell by its 
ability to bind to p53 specific DNA-binding sequences (Ljungman, 2000). Moreover, p53 
has been called the guardian of the genome(Lane, 1992) due to its role in maintaining the 
genome stability by avoiding mutations (Figure 1.3)(Levine & Oren, 2009; Strachan & 
Read, 1999).     
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Figure 1.3: Scheme for p53 functions and different p53 activating signals. A verity of stress 
signals including oxidative stress, hypoxia, ribonucleotide depletion, mitotic apparatus 
dysfunction, oncogene activation, DNA replication stress, double-strand breaks and others lead 
to p53 liberation from MDM2 then to activate different p53 target genes or protein- protein 
interactions. Afterwards, cell response depends on stress severity (Levine & Oren, 2009). 
 
Many of p53 target genes have been determined. Numerous of them encode proteins that 
are induced in cell cycle and apoptosis control. From the major p53 direct effectors that we 
study here are p21 and BAX. p21 is a cyclin-dependent kinase inhibitor, which when 
induced, promotes cell growth arrest or death and represents an important regulator for 
transition from G1 to S phase in the cell cycle(Tang et al., 1998). Bax is a proapoptotic gene. 
Both are transactivated directly by p53(Levine & Oren, 2009). In addition to its genomic 
function, p53 has non-transcriptional biochemical activities that are induced in part by 
interacting with other proteins in the cytoplasm and in the nucleus of the cell. The apoptosis-
regulatory Bcl2 protein family is an example for cytoplasmic proteins that are inhibited by 
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p53 to increase the mitochondrial outer membrane permeabilization then to release of 
cytochrome C and apoptosis (Vaseva & Moll, 2009).  
p53 protein level in the cell is tightly regulated by MDM2. p53-MDM2 interaction is from 
the most important protein- protein interaction in the cell (Levine & Oren, 2009). MDM2 is 
recognized as p53 gatekeeper because of its ability to inhibit p53 activity and keeping p53 
at the basal level in normal cells in order to prevent apoptosis. That could be accomplished 
by different ways. First, by blocking p53 transactivation function, and second, by promoting 
the ubiquitylation and proteosomal degradation of p53, which is catalyzed by  E3 ubiquitin 
ligase activity of MDM2 (Momand, Zambetti, Olson, George, & Levine, 1992; Oliner et al., 
1993). Moreover, MDM2 gene expression is regulated by p53 in a negative feedback loop 
for p53 protein at the activity level and in a positive feedback loop for MDM2 at the 
transcription level (Wu, Bayle, Olson, & Levine, 1993).  
A huge body of research has published that TP53 gene is mutated or deleted in about half of 
all human cancer types and that TP53 is the most studied gene in several cancer specimens 
(Espinosa & Emerson, 2001; Levine & Oren, 2009; Vogelstein, Lane, & Levine, 2000). 
Moreover, TP53 mutation occurrence represents the most between all tumor suppressor 
genes and from the highly important drivers for carcinogenesis in different cancer 
types(Forbes et al., 2011; Myers et al., 2016). Of the frequent widespread tumors related to 
TP53 mutations are breast, colon, lung, head and neck cancers (Petitjean et al., 2007). In 
breast cancer, TP53 gene is mutated in nearly 34% of breast cancer patient’s samples based 
on the cBioPortal database tool (Cerami et al., 2012; Gao et al., 2013; The cBioPortal for 
Cancer Genomics, 2016). Moreover, patients with breast cancer expected to have low 
survival rate when they have TP53 mutations (Olivier et al., 2006). Noteworthy, TP53 
mutations can be inherited in the germlines and causes tumor formation in childhood such 
as in Li-Fraumeni syndrome. Which, also known as the sarcoma, breast, leukemia and 
adrenal gland (SBLA) syndrome (F. P. Li & Fraumeni, 1969).  
The majority of TP53 mutations in breast cancer are somatic mutations (Walerych, Napoli, 
Collavin, & Del Sal, 2012). These mutations are mostly missense substitutions (Figure 1.4), 
which include contact mutations that affect p53 DNA-binding ability with low influence on 
p53 conformation and structural mutations that intensively interrupt p53 conformation(D. 
P. Liu, Song, & Xu, 2010). There are different TP53 hotspot mutations at different codon 
positions such as R175H/G, R248Q/W/G and R273H/C/G/L/P which all are in the p53 
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DNA-binding domain (Figure 1.5) (Cerami et al., 2012; Gao et al., 2013; The cBioPortal for 
Cancer Genomics, 2016). 
TP53 mutations can lead either to loss of tumor suppression activity or gain of a new 
function that enhances cancer development (D. P. Liu et al., 2010) and causes different 
functional oncogenic phenotypes (Bullock, Henckel, & Fersht, 2000). Gain of oncogenic 
functions was identified in the very popular TP53 contact mutations such as R273H and 
R248W, and structural mutations like R175H and R248Q (D. P. Liu et al., 2010).   
  
 
 
 
 
 
 
 
 
Figure 1.4: TP53 mutation types and distribution in breast cancer samples. 
Microarray results showing the expression level of different TP53 mutation expression 
among 2173 breast cancer samples as indicated on the y-axis. The y-axis shows the 
relative expression of the different types of mutations relative to TP53 mRNA 
expression (Cerami et al., 2012; Gao et al., 2013; The cBioPortal for Cancer Genomics, 
2016).   
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Figure 1.5: The distribution of hotspot mutations on TP53 in breast cancer. The y-axis indicates the 
number of TP53 mutations among 2173 breast cancer samples. Green, black, and red colors of single dots 
refer to missense, truncating (Nonsense, Nonstop, Frameshift deletion, Frameshift insertion, Splice site) and 
Inframe (deletion and insertion) mutations, respectively. Blue color represents wild-type p53. The x-axis 
shows the position of the mutations on the respective domains in p53 protein (Cerami et al., 2012; Gao et 
al., 2013; The cBioPortal for Cancer Genomics, 2016). 
 
1.5. HRAS G12V and TP53 variants combination role in cancer 
transformation   
 
A range of studies showed that when mutated TP53 is transfected into normal cell lines, it 
could collaborate proficiently with several oncogenes, remarkably HRAS, and transform 
primary cells in vitro. In addition, when mutant TP53 is overexpressed, it leads to cell 
immortalization (Eliyahu, Raz, Gruss, Givol, & Oren, 1984; Jenkins, Rudge, & Currie, 
1984; Parada, Land, Weinberg, Wolf, & Rotter, 1984). Besides, further studies described 
that, the combination between the HRAS G12V and inhibition of TP53 gene is highly 
coupled with cancer transformation (Buganim et al., 2010). Noteworthy, that combination 
between oncogenic RAS and inactive/or mutated TP53 can promote tumorigenesis in lung 
and pancreatic tumors (Solomon, Brosh, Buganim, & Rotter, 2010) by affecting virtually all 
the hallmark processes that are associated with tumorigenesis, including inflammation, 
proliferation, motility, metastasis, and angiogenesis (Hanahan & Weinberg, 2000). 
Previously, in an in vivo study, a comb 4ination of constitutively active HRAS and 
inactivated p53 was shown to lead to G2 arrest bypass, moving to cancer transformation, 
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activation of epithelial to mesenchymal transition and to a rise in stemness in urothelial cells 
(He, Melamed, Tang, Huang, & Wu, 2015). In another study, a mouse model was used to 
express R172H TP53 hotspot mutation and activated KRAS G12D in the pancreas. This 
combination led to high level of invasion and metastatic carcinoma (Hingorani et al., 2005). 
 
p53 and RAS are master proteins that regulate many downstream targets. The molecular link 
between these two proteins was the focus of different studies (Buganim et al., 2010). For 
example, the crosstalk between them was shown to control   the expression of some specific 
gene cluster that regulate precancerous secreted molecules, which are called Cancer related 
Gene Signature (CGS) (Buganim et al., 2010). From the secreted molecules that were shown 
to be affected by active HRAS and to have pro-cancerous activity, present in the CGS, are 
some chemokines like CXCL1, CXCL2 and CXCL3, interleukins such as IL-1b, IL-6 and 
CSF2 and extracellular matrix related proteins as MMP-3, CLECSF2 and TREM-
1(Solomon et al., 2012). Also, ATF3 and BTG2, which are p53 downstream target genes, 
were found to produce inhibitors for RAS-induced transformation(Solomon et al., 2010). In 
a previous research, wild-type p53 was shown to suppress the expression and activity of 
CGS genes through different mechanisms. One of these mechanisms is that p53 activates 
BTG2, then BTG2 binds with HRAS G12V and deactivates it. Moreover, p53 stabilization 
leads to ATF3 activation, which binds with CGS genes and repress their activity (Solomon 
et al., 2012). Another evidence that links p53 and RAS is the fact that p53 protein is 
stabilized in case of RAS activation via diverse molecular loops that involve ARF, DMP1, 
PML, and PRAK proteins (Buganim et al., 2010). 
 
1.6. Problem statement and motivation of the study 
 
Breast cancer is a heterogeneous disease. Many researchers are trying to unravel the genetic 
changes and mechanisms that contribute to breast epithelial cell transformations. The 
imbalance between the activities of tumor suppressors and oncogenes is the common event 
that leads to cancer transformation (Solomon et al., 2010). Also, two or more genetic 
alterations are required for tumorigenesis. Our project aimed to create breast cancer 
transformation model that could be employed to study breast cancer in two hit system 
context.   
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Studying particular cancer mutations would help in understanding how do different types of 
mutations could affect cancer prognosis and treatment regimens (Myers et al., 2016). In fact, 
several clinical trials were based on targeting RAS or p53 pathway (Levine & Oren, 2009). 
Therefore, studying the effect of HRAS function in the context of different p53 variants in 
the context of breast cancer might help in understanding the differential behavior of different 
breast cancer tumors. 
 
1.7. Hypothesis 
 
This project is based on the assumption that various gene transcription reprogramming lead 
to different changes in oncogenic cellular phenotypes. We hypothesize that in conjunction 
with HRAS G12V overexpression, cells harboring different TP53 variants will behave 
different and thus the expression of different cell phenotypes will appear.                                                   
 
1.8. Aims of study 
 
1.8.1. The main goal of this research is to create different breast cancer transformation 
models by transforming normal mammary epithelial cell lines, MCF10A cells, that contain 
different TP53 gene variants with HRAS G12V.  
1.8.2. Testing the differences in distinct cellular phenotypes (cancer hallmarks) caused by 
the combination between HRAS G12V and different TP53 variants.  
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Chapter 2  
 
 
2. Materials and Methods 
 
2.1. Materials 
 
    Table 2.1: Equipment and tools 
# Name  Company  
1 Analytical Balance METLER TOLEDO AB104 
2 Autoclave HIRAYAMA HV-110 
3 Vortexes: SA6, Genie 2, Reax top Stuart Scientific, neoLab, 
Heidolph 
4 Biological hood (HERA guard) Heraeus 
5 Biofuge Stratos Reconditioned Heraeus 75005289R 
6 Biofuge Fresco Heraeus 75005521 
7 Digital dry bath Labnet 
8 Elisa reader BioTek EL-X800 
9 Hera cell 150 CO2 Incubator Heraeus 
10 Inverted microscope Olympus ck40-SLP 
11 Labofuge 200 centrifuge Heraeus 
12 RT-PCR (Applied Bio-systems 7500 
Real Time PCR 
13 GlobMax discover reader   Promega 
14 Axiovert 40 CFL microscope with built-in camera 
Axiocam MRC 
Carl Zeiss 
15 Benchtop centrifuges: Labofuge 200, Biofuge fresco Therom Fisher Scientific 
Heraeus  
16 Cell counter CASY Casy , Innvatis 
17 Cell culture hood – HERAsafe Safety Cabinet KS12  Thermo Fisher Scientific 
Heraeus 
18 Cell culture incubator (37 ℃   , 5% CO2)  Binder 
19 Computers hp, Fujitsu, Siemens  
20 Floor centrifuge – Heraeus Multifuge 4KR  Thermo Fisher Scientific 
21 Heraeus Sepatech Verifuge 3.0 R Heraeus 
22 Freezer -20 ℃   Libherr 
23 Freezer -80 ℃   ,VIP Sanyo 
24 Freezing container  Sigma-Aldrich 
25 Fridge 4℃    Liebgerr 
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26 Horizontal roller shaker ,RM5 neoLab 
27 Ice machine  Hoshizaki 
28 Image Xpress microscope  Molecular Device  
29 Light microscope Wilovert S Hund Wetzlar  
30 Liquid nitrogen storage system  Cryotherm  
31 LSM cell Observer  Carl Zeiss 
32 MilliQ Biocel Water Purification System  Millipore 
33 Multichannel pipette  Eppendorf  
34 Multistep pipette Biohit ( 5-100 μl)  Biohit 
35 Multistep pipette Ripette ( 200 μl – 5 ml)  Ritter Medical  
36 Thermomixer comfort Eppendorf 
37 Olympus Scanning microscope  MJ Research  
38 Pipettes ( 0.5 – 1000 μl)  Eppendorf , Gilson 
39 Safety hood Waldner 
40 Scanner  Epson 
41 Suction device for cell culture  neoLab 
42 SPIN-micropipette site Nano Spinreact 
43 Ultracentrifuge BECKMAN COULTER 
optima LE80H 
44 Water Bath Orbital Shaking Grant OLS200 
45 Water Baths  Grant LTD6G, Julabo TW20 
46 PCR machine 96 well  
 
Applied Biosystem #9902 
47 Neubauer count chamber ( 0.1 mm depth ) BLAUBRAND 
 
 Table 2.2: Reagents and Chemicals  
 
# Name  Company 
1 DMEM-F12 medium Biological industries , Gibco  
 DMEM medium Invitrogen  
2 RPMI (1640) medium Gibco  
3 Horse serum  Biological industry  
4 Fetal bovine serum (FBS) Gibco  
5 Hydrocortisone  Sigma-Aldrich  
6 Insulin  Sigma -Aldrich 
7 Epidermal growth factor (EGF)  Sigma -Aldrich 
8 Cholera toxin  Sigma -Aldrich 
9 L-Glutamine  Biological industries  
10 Penicillin/streptomycin  Biological industries  
11 Dimethyl sulfoxide  Sigma -Aldrich 
12 Sterile phosphate buffer saline PBS  Biological industries  
13 Puromycin  ,  Sigma -Aldrich 
14 XTT kite  Biological industries  
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15 Trypane blue  Biological industries  
16 Isopropanol biological gradient  Sigma -Aldrich 
 
17 Ethanol biological gradient  Sigma-Aldrich  
18 Chloroform biological gradient  Sigma -Aldrich 
19 qScript™cDNA synthesis kit  Quanta Biosciences  
20 SYBR® Green  Applied Biosystems  
21 TRIZOL  Sigma -Aldrich 
22 Diff-Quick System  Sigma -Aldrich 
23 0.5% and 0.05% Trypsin-EDTA  Invitrogen  
24 Agrose Sigma-Aldrich 
25 BCA protein assay kit Thermo Fisher Scientific  
26 Choroform  Merck 
27 Deoxynucleoside triphosphates (dNTPS) New England Biolab 
28 DNA Loading dye (6x) Thermo Fisher Scientific  
29 GeneRuler 1 kb DNA Ladder Thermo Fisher Scientific 
30 GeneRuler 100 bp DNA Ladder Thermo Fisher Scientific 
31 Geneticin G148 (Neomycin) Gibco  
32 Methanol Sigma-Aldrich 
33 Nuclease Free Water  Ambion 
34 Phosphate buffered saline ( PBS) Gibco 
35 OptiMEM Invitrogen  
36 Lipofectamine  Invitrogen  
37 Matrigel matrix Corning  
38 Anti-p53 Santa Cruz Biotechnology 
39 Anti-B-Actin Santa Cruz Biotechnology 
 
Table 2.3: Cell lines 
# Name  Origin  
1 MCF10A TP53KO Sigma-Aldrich 
2 MCF10A Wtres  
DKFZ Genomic and 
Proteomics core facility  
3 MCF10A R248Q 
4 MCF10A R175H 
5 MCF10A R273H  
6 HEK293FT Invitrogen  
7 MCF10A parental  ATCC 
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    Table 2.4: Plasmids 
# Name  Origin  
1 rwpLX305_hRAS_G35T_IRES_Puro  K 1  
DKFZ ,  
Genomic and 
Proteomics core facility. 
Kindly provided by  
Dr. Rainer Will  
2 rwpLX305_MCS_HA_IRES_Puro  K1 
 
3 
 
rwpLX305_RedFF_HA_inakt_IRES_Puro  K1 
4 PsPAX2 Addgene 
5 PMD2.G Addgene 
 
2.2. Methods 
 
2.2.1. Cell culture  
 
Stable MCF10A cell lines expressing different TP53 mutations were established by 
the Genomics and Proteomics Core Facility at the DKFZ- Germany. These lines were 
generated by overexpressing different p53 constructs in   MCF10A TP53KO cells 
from Sigma-Aldrich (catalogue number CLLS1049). Overexpression was achieved 
by using the lentiviral vector pLx305 that expresses either FLAG-tagged TP53 
R175H or TP53 R248Q or wild-type TP53.  
All MCF10A cell lines were cultured in DMEM-F12 supplemented with 5% horse 
serum, 20 ng/mL EGF, 0.5μg/mL hydrocortisone, 1% L-glutamine, 100ng/mL 
cholera toxin, 1% penicillin/streptomycin (50 U/μL penicillin and 50μg/mL 
streptomycin as final concentration) and 10μg/mL insulin. DMEM medium 
supplemented with high glucose and 10% FBS was used to culture HEK293FT cells.  
Cells were passed every 3-4 days. For this purpose, the medium was eliminated and 
cells were washed with 5 mL PBS X1 one time. Afterwards, 3 mL trypsin (0.05% 
concertation) was used followed by incubation for 15-20 minutes in 37 ℃, 5% CO2 
incubator. Then, 5 mL full growth medium was added to detach the cells. Cells were 
counted by using Neubauer counting chamber (0.1 mm depth) and 0.5x106 cells were 
seeded in 75cm2 flasks.  
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2.2.2. Cells cryopreservation 
  
To prepare the freezing medium, full growth DMEM-F12 medium supplemented with 
20% horse serum and 10% DMSO was used. Trypsinized cells were collected and 
then counted with Neubauer counting chamber and spun down. The preferred quantity 
of the cells (1 – 2 x 106 cells/mL) was resuspended in the freezing medium and was 
distributed into cryo-vials. To obtain a gradually cooling rate of the cells (1℃ /min), 
cryo-vials were placed inside freezing container with isopropanol and left into a -
80℃ deep freezer. Finally, cells were moved to liquid nitrogen tank for long term 
storage.  To restore and thaw the cells from freezing, a cryo-vial holding cells were 
resuspended in 1 mL full growth medium and transferred into 75 cm2 flask having 15 
mL full growth medium.   
 
2.2.3. Generation of stable cell lines pools  
 
Viral particles production and Transduction  
 
2x105 of HEK293FT cells were seeded on poly-lysine-coated 100 mm dish with full 
growth medium. Next day, cells were transfected using the following procedure. First, 
to prepare transfection mixture, 1450 μL OptiMEM and 50 μL lipofectamine were 
mixed and incubated for 5 minutes at room temperature. To prepare viral particles, 
we mixed 7 ug of psPAX2 packaging vector with 6 ug of retroviral transfer vectors 
(rwpLX305_ RedFF _HA_ inakt_ IRES_ Puro K1 or rwpLX305 _MCS _HA _IRES 
_Puro K1 as controls, or rwpLX305_ hRAS_G35T _IRES _Puro K 1), and 3 ug 
pMD2.G envelope vector. Then this plasmid mixture was mixed with transfection 
mixture and incubated for 30 minutes at room temperature. Afterwards, this mixture 
was added to HEK293FT cells and incubated for 5 hours at 37 ℃, 5% CO2 incubator. 
Later, the transfection solution was replaced with 10 mL DMEM full growth medium.  
48 hours following transfection, the media containing the viral particles was collected 
and frozen until being used for cell infection.  
For infection, 5X105 cells / well were seeded in 6 well plate in full growth medium. 
Next day, DMEM-F12 medium that was collected from HEK293T cell plates was 
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centrifuged, and the supernatant was collected. 2ml of this medium was afterwards 
mixed with polybrene and added to cells for two days at 37 ℃, 5% CO2 incubation.  
 
2.2.4. Selection 
 
To select for clone pools, the transduction medium was changed with fresh full 
growth medium containing the appropriate selection antibiotics, Puromycin (stock = 
10 mg/mL, diluted 1:5000, final concentration 1μg/ml) and Geneticin (Neomycin, 
stock = 50 mg/mL, diluted 1:100, final concentration 500 μg/ml). The selection 
antibiotic was kept on cells until control non infected cells totally died.  
 
2.2.5. Cell count using fluorescent microscope  
  
1000 cells were seeded in 96 well plates in full growth medium. After 7 hours of 
incubation, the medium was aspirated and replaced with DMEM-F12 medium 
supplemented with 0.9% horse serum, 1 or 0 ng/mL EGF, 0.5 μg/mL 
hydrocortisone,100 ng/mL vibrio cholera toxin and 10 μg/mL insulin. For the two 
EGF concentrations, ten replicates were used. The number of the cells in the seeding 
control plate was measured after 24 hours’ of incubation, and 72 hours’ incubation 
for the assay plate by adding 1:5000 dilutions of Hoechst staining. The cells count 
refers to the nuclei count by using the Molecular Devices microscope.   
 
2.2.6. Cell count using Neubauer counting chamber 
 
Triplicates of 3x104 cells were seeded in 6 well plates and incubated at 37 ℃ , 5% 
CO2 for 24 hours. Next day, the attached cells were collected in 15 ml tubes and 
centrifuged at 1200 RPM for 10 min. Then, the supernatant was eliminated and cells 
were resuspended in full growth medium. Lastly, cells were counted by using 
Neubauer counting chamber.  
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2.2.7. XTT test  
 
Triplicate of 2x103 cells/well were seeded in 96 well plate and incubated at 37℃   , 
5% CO2 for 24, 48, 72 hours and cell proliferation was assessed by using XTT stain 
according to manufacturer. 
 
2.2.8. Wound healing assay  
 
Triplicates of 2x105 cells/well were seeded in 12 well plates in full growth medium 
and incubated at 37 ℃, 5% CO2 until having 100% growth confluence. To generate 
wound, cell monolayer was scratched using 10μl pipet tip. Afterwards, floating cells 
were washed out using PBSX1. Finally, cells were supplied with starvation medium 
that lacks serum and wound was photographed over 24 hrs.  
 
2.2.9. Survival assay  
 
200 and 400 cells were seeded in 6 well plates in full growth medium. Every 3-4 days 
the medium was changed until visible colonies were seen. Later, the growth medium 
was removed and the plates were washed using PBS x1. Next, cells were fixed for 15 
minutes by using absolute methanol and then left to air dry. After fixation, colonies 
were stained using Coomassie blue, washed and counted using naked eye.  
 
2.2.10. Anchorage-independent growth assay   
 
4X104 cells were seeded in 10 cm cell culture plates and ultra-low attachment plates 
in full growth medium and incubated at 37 °C and 5% CO2 for 14 days. The spheroids 
that formed were monitored, photographed, and counted.  
 
2.2.11.  Soft agar assay   
 
The assay medium is composed of a lower and upper agar layers. The lower layer was 
prepared by using RPMI 1640 medium containing 1% Agar. 2 mL of this mixture 
was poured in each well of 6 well plates and kept at 4 °C for at least one hour. Then, 
19 
 
2X104 cells were mixed with 1.2 mL of the upper layer that contained 0.7% agar. This 
cell mixture was then added on the top of the lower layer and put back in CO2 
incubator until colonies were visible to naked eye.                              
 
2.2.12. Matrigel 3D culture assay  
 
First each well of 8 well chamber slide was coated with 40ul of growth factor reduced 
Matrigel and left for at least 15 minutes in the incubator at 37C until it became solid. 
Then 3000 cells were mixed with 400ul growth medium containing 4% Matrigel and 
added to the Matrigel bottom layer. The assay chamber slide was then incubated in 
the incubator for two weeks. Forming mammospheres were photographed using 
inverted microscope.   
 
2.2.13. RNA Extraction  
 
Cells were seeded in 10 cm cell culture plates in full growth medium and incubated 
at 37 °C and 5% CO2 for 24 hours. Next, the medium was aspirated 1 mL Trizol was 
added to the plates and incubated on ice for 5 minutes. Then, the cells collected in 
RNase free tubes and incubated on ice. Afterwards, the collected cells mixed 
thoroughly with 200 μL chloroform using vortex and incubated for 15 minutes on ice. 
The tubes were centrifuged for 15 minutes at 12000 RPM at 4 °C, then the supernatant 
was transferred to new RNase free tubes and 500 μL pre-coold isopropanol was 
added, mixed and incubated for 15 minutes on ice. Subsequently, the tubes were 
centrifuged at 12000 RPM for 15 min at 4 °C. Next, the supernatant was discarded 
and 500 μL 70% Ethyl alcohol was added. Thereafter, the tubes were centrifuged at 
12000 RPM for 10 min at 4 °C and the pellet left to dry for 1 minute. Later, the pellet 
was resuspended with DEPC treated water and incubated at 60 °C for 5 minutes in 
dry bath. Lastly, the concentration of the extracted RNA was measured and run by 
gel electrophoresis. 
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2.2.14. cDNA synthesis  
 
In PCR tubes, 1 μg of extracted RNA was mixed with 4 μL RT buffer, 1μl enzyme 
and ultra-pure water added to complete the mix volume to 20 μL. Later, the tubes 
were put in PCR machine according to manufacturer recommendations.   
 
2.2.15. Real time PCR  
 
In 96 q-PCR well plate, 3 μL of diluted cDNA (1:10), 1 μL of primer (10 μM), 10 μL 
SYBR® Green and 6 μL ultra-pure water were added per well. Then, the q-PCR plates 
were sealed and centrifuged for 5 minutes. Lastly, the plate was put in q-PCR machine 
with pre-conditioning at 50 °C for 2 minutes, activation at 95 °C for 10 minutes, 
denaturation at 95 °C for 15 seconds and annealing and extension at 60 °C for 1 
minute. 
 
2.2.16. Western blot 
 
Cells were lysed by using RIPA lysis buffer containing 1x Complete Mini Protease 
Inhibitor Cocktail, 1x PhosSTOP phosphatase inhibitor. All the steps were done on 
ice. Cell scraper was used to detach cells, and the cell lysates were incubated at 4 ℃ 
for 10 minutes. The lysates were collected and centrifuged at 13000 rpm at 4 ℃. The 
concentration of protein in the supernatant was measured using BCA Protein Assay 
kit (Thermo). 40ug protein was used for gel loading after mixing the sample with 
sample buffer. Before loading samples mixed with sample buffer were boiled for 
10min in a dry path. Polyacrylamide gels with the concentration of the running gels 
12.5% and stacking gels 4% were prepared. A prestained protein ladder was used as 
molecular weight marker. The separation was done at 100 V/cm for 1.5 hours in the 
1x SDS-PAGE running buffer 250 mM Tris base and 1.92 M Glycine.  Proteins on 
the gel were transferred to Millipore`s PVDF membrane Immobilon-FL using the 
semi-dry method. The transfer was done for 60 minutes at 25V. Before adding 
antibodies, membranes were blocked by using 5% skim milk in 1XTTBS. After 
blocking, the membrane was incubated with the primary antibody (P53 Santa Cruz 
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Biotechnology) which was diluted in the blocking solution for overnight at 4 ℃. The 
next day, the membrane was washed 3 times, 10 minutes each, with TBST and then 
incubated with secondary antibody anti-mouse conjugated to DyLight 680 in 1:10000 
dilutions in TBST. The membrane was washed 3 times each10 minutes with TBST 
and scanned with infrared scanner at 700 and 800 nm. B-Actin housekeeping gene 
was used as a loading control. 
 
2.2.17. Primer design 
 
The primers that were used in this study are listed in the table below and was designed 
by using Primer 3 software (http://primer3.ut.ee/). 
 
   Table 2.5: List of the designed primers 
No Gene Primers Reference 
1 HRAS F.P_5'- tgccatcaacaacaccaagt-3' 
R.P-5'- agccaggtcacacttgttcc-3' 
NM_001130442.2 
2 Bax F.P_5'- ggttgtcgcccttttctact-3' 
R.P-5'- aagtccaatgtccagcccat-3' 
NM_001291428.1 
3 BCL2 F.P_5'- gccctgtggatgactgagta-3' 
R.P-5'- gaaatcaaacagaggccgca-3' 
NM_000633.2 
4 Cyclin B1 F.P_5'- gtcaccaggaactcgaaaat -3' 
R.P-5'-ttaccaatgtccccaagagc-3' 
NM_031966.3 
5 Slug F.P_5'- atacagtgattatttccccg -3' 
R.P-5'- agcggtagtccacacagtga-3' 
NM_003068.4 
6 Snail1 F.P_5'- acactggcgagaagccctt -3' 
R.P-5'- gcctggcactggtacttctt -3' 
NM_005985.3 
7 Twist1 F.P_5'- cggagacctagatgtcattg-3' 
R.P-5'- cgccctgtttctttgaattt-3' 
NM_000474.3 
8 Wnt5A F.P_5'- atgaagaagtccattggaat -3' 
R.P-5'- ctgggcgaaggagaaaaata -3' 
NM_003392.4 
9 Cyr61 F.P_5'- atctgcagagctcagtcaga-3' 
R.P-5'- tcttggggacacagaggaat-3' 
NM_001554.4 
10 Bad F.P_5'- ctcctttaagaagggacttc-3' 
R.P-5'- gatgtggagcgaaggtca-3' 
NM_004322.3 
11 GLUT 1 F.P_5'- agaaggtgatcgaggagttc-3' 
R.P-5'- agagaaggagccaatcatgc-3' 
NM_006516.3 
12 IDH 1 F.P_5'- ctacatagctatgatttaggc -3' 
R.P-5'- ctcaaccctcttctcatcagg-3' 
NM_001282386.1 
13 p21 F.P 5’- cgtcaaatcctccccttcct-3’ 
R.P 5’- atgggttctgacggacatcc -3’ 
NM_001291549.1 
14 HUBC 
 
F.P 5’- gtcgcagttcttgtttgtgg-3’ 
R.P 5’-gatggtgtcactgggctcaa-3’ 
NM_021009.6 
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Chapter 3  
 
 
3. Results  
 
3.1. Generation of HRAS G12V MCF10A clones harboring different TP53 variants   
 
To investigate in what way HRAS G12V overexpression influences cellular phenotypes in 
MCF10A cells expressing different TP53 variations, the first goal of this project was to 
create different MCF10A HRAS G12V clones harboring different TP53 variants. To do so, 
either HRAS G12V expressing or empty retroviral viral vectors were used to stably 
transduce MCF10A cells that express different TP53 constructs.  Here, we expressed 
HRAS G12V in TP53 knockout cells MCF10A cells expressing either wild-type TP53 
(control cells) or TP53 with R175H mutation or in cells lacking TP53 (TP53 knockout 
(KO) cells). To validate the generation of the clones, we used real time PCR to test the 
expression of HRAS and TP53 using HRAS and TP53 specific primers described in table 
1. Based on our Real time PCR results we were able to generate the relevant clones. For 
example, HRAS expression was higher in MCF10A cells that were transduced with HRAS 
G12V construct compared to its expression in MCF10A cells that transduced with empty 
vector construct (Figure.3.1). The same was obtained with the different TP53 clones where 
TP53 expression is high in cells overexpressing either Wt or R175H TP53 and low in TP53 
KO cells (Figure.3.1). Altogether, our results show that we were able to generate different 
MCF10A clones overexpressing HRAS G12V in combination with different TP53 
variations.  
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3.2.  Phenotypic change characterization of HRAS transduced MCF10A cells  
 
To examine the effects of HRAS overexpression in various TP53 transduced MCF10A 
cells, several functional assays were performed. Different cancer hallmarks were tested by 
a couple of functional assays, such as cell nuclei counting assay, XTT assay, total cell 
count assay, migration assay, anchorage-independent growth assay, survival assay, soft 
ager assay and Matrigel 3D culture assay.  
 
3.2.1.1.  Effect of HRAS overexpression in combination of different TP53 variants on 
MCF10A cell proliferation  
 
Cancer cells are characterized by uncontrolled growth and proliferation which is an 
important cancer hallmark (Hanahan & Weinberg, 2011). HRAS is recognized to 
enable cell growth and proliferation (Karnoub & Weinberg, 2008), whereas p53 
protein stops cell proliferation(Levine & Oren, 2009). Hence, the combination of 
HRAS overexpression with TP53KO or Wt TP53 or TP53 R175H mutation was 
hypothesized to affect MCF10A cells proliferation in different manners. To test the 
Figure 3.1: HRAS and TP53 expression levels in transduced MCF10A cells. (A) Real time PCR results 
showing the relative expression level of HRAS gene relative to the house keeping gene UBC. All gene 
expression folds were calculated relative to the expression level in parental cells. Bars indicate the standard 
deviation of the mean of three biological replicates. (B) Western blot for p53 protein. B-Actin was used as a 
protein loading control. The statistical significance of the results was determined by measuring the p value. (** 
means that p-value>0.05 and * means that p-value <0.05). 
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previous hypothesis, several cell proliferation assays, i.e. nuclei counting, total cell 
counting and XTT were performed.   
Nuclei counting assay was carried out by using fluorescent microscope (MoleDev), 
which counts nuclei of the cells that trap Hochest stain (Figure 3.2). However, 
because HRAS G12V clones grow in clumps (Figure 3.2), the microscope was not 
able to count all cell nuclei in a reliable manner. As shown in Figure 3.2, there is a 
discrepancy between the number of nuclei that were captured (Blue color) and the 
number of nuclei that the microscope had counted (red color) and thus we didn’t 
present the results of this experiment. As it appears from these figures, the microscope 
failed to count all cells that were in clumps (indicated by arrows) (Figure 3.2).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Automatic nuclei counting assay using fluorescent microscope. 
Representative micrographs showing how does fluorescent microscope capture 
figures and count the cells.  Captured cell nuclei appear in blue color and the 
counted nuclei appear with the red color. Each of the above pictures represent 
a quarter of the field after 2 days of cell culture. White arrows indicate cell 
clumps that the microscope was not able to count them. 
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Because of the technical issues we faced with microscope nuclei cell count, we did 
total cell count using chamber slide technique. Also, in this manual total cell count 
assay, the results were also not reliable because the aggressive cells harboring 
HRAS mutation formed clumps (Figure.3.3) that didn’t adhere very well to cell 
culture plates and were washed out during cell count procedure. Figure.3.4 shows 
a representative result that we obtained using total cell count technique. To try to 
overcome the technical problems we faced with previous techniques, we tried to 
learn about cell proliferation behavior by measuring cell metabolic activity by 
using XTT assay. But also, here we could not get reliable results for the same 
reasons mentioned above.  As shown in Figure.3.5, the highest proliferative rate 
was observed with MCF10A cells with TP53 Wtres and HRAS G12V, which is not 
in concordance with our eye observations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Transduced MCF10A cell morphology. Representative micrographs 
showing differences in cell morphology that accompany the different transduction 
combinations. The upper photos represent the cells with empty vector and the lower photos 
represent the cells with HRAS G12V.  
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Figure 3.4: Relative proliferation rate for the transduced MCF10A clones using total count 
assay. The bars show the effects of HRAS overexpression on cell proliferation measured by total 
count assay for two days. Cells were counted in triplicates. Y axis represents the relative 
proliferation rate index correlated to TP53 Wtres MCF10A cell lines at day 1.  
Figure 3.5: Relative proliferation rate for the MCF10A transduced clones using XTT 
assay. The graph shows the effects of HRAS overexpression on cell proliferation monitored by 
XTT assay for three days. Cells were tested in triplicates per each point of time. Y axis 
represents the relative proliferation rate index correlated to day zero.  
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3.2.1.2. HRAS overexpression and TP53 variants effects on MCF10A cell migration  
 
A further key cancer cells hallmark is the acquisition of cell migratory phenotype. 
HRAS overexpression is associated with enhancement of cell mobility and 
metastasis of tumor cells (Solomon et al., 2010). However, in normal cells as a 
defense mechanism to prevent cancer transformation, p53 is involved in 
senescence, cell-cycle arrest, or cell death (Lin et al., 1998) as well as in inhibiting 
migration and metastasis. When TP53 is lost or has gain of function mutation, that 
increases the metastatic potential of breast cancer (Powell, Piwnica-Worms, & 
Piwnica-Worms, 2014). In fact, as migration is important for metastasis of the 
tumor cells, the combination between HRAS G12V and TP53 KO or TP53 with 
R175H mutation was hypothesized to increases MCF10A cells migration. To test 
this hypothesis, wound healing assay was performed.  As shown in Figure 3.6, 
HRAS increased cell migration capacity in all cell lines compared to cells infected 
with EV. The most drastic effect on cell migration was observed in the 
combination of HRAS G12V with TP53 KO in MCF10A cells. In TP53 R175H and 
HRAS G12V combination, the cells failed to form a monolayer because they tend 
to grow in clumps, which made it difficult to compare the migration capacity of 
these cells to others. 
 
 
 
Figure 3.6:  Effect of HRAS overexpression on migration of different TP53 manipulated MCF10A 
clones. Representative micrographs taken for the indicated cells at 0 h as well as after 19 h after wounding 
cell monolayer.  
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3.2.2. Effect of HRAS overexpression on cell survival of different MCF10A TP53 
clones  
 
One of cancer cell tumorigenesis features is independence on exogenous stimulus for 
growth and survival (Hanahan & Weinberg, 2000). HRAS overexpression correlates 
with increased cancer cell resistance to death (Solomon et al., 2010). In order to test the 
effect of HRAS G12V overexpression on different MCF10A TP53 clone survival, we 
did colony formation assay.  
Unexpectedly, HRAS showed an effect only on cells expressing Wt TP53 (Fig.3.7). In 
contrary HRAS seemed to reduce cell survival in TP53 KO and TP53 R175H cells (Fig. 
3.7). Also, these results didn’t not match out eye observation. Moreover, in these two 
combinations, cells grew in clumps and detached from the plates when we tried to stain 
and enumerate them by the end of the assay.  
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Figure 3.7: HRAS overexpression effect on survival of different MCF10A TP53 clones.  
Representative statistical analysis of the survival rate of HRAS transduced MCF10A cells 
monitored using colony formation assay. Cells were tested in triplicates for 12 days and the bars 
represent the standard error of the mean.  
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3.2.3. HRAS overexpression and TP53 variants effect on MCF10A anchorage-
independent growth  
 
Anchorage-independent growth is one of the frequent events that could occur during cell 
transformation in solid tumors including breast cancer and it reflects the metastatic 
potential of  transformed cells (Wise, Duhachek-Muggy, Qi, Zolkiewski, & Zolkiewska, 
2016). The cell ability to grow in suspension, mamosphere formation, and anoikis (a form 
of apoptosis)-resistance are important for cancer cell to resist cell death in suspension and 
thus metastasis to distant organs (Dontu et al., 2003). Normal breast epithelium cell line 
MCF10A exhibits absence of tumorigenic feature and lack of the capability of anchorage-
independent growth (Debnath, Muthuswamy, & Brugge, 2003). In this framework, HRAS 
overexpression with TP53KO or TP53 with R175H mutation were hypothesized to 
stimulate anchorage-independent growth of MCF10A cells. Hence, anchorage-independent 
growth assay, by using coated and uncoated plates was used in order to prove this 
hypothesis. Cells were counted by using Trypan blue stain, which stains dead cells only. 
As we mentioned above, the cells form clumps, which hard to count and that give unreliable 
data as shown in Figure 3.8. 
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Figure 3.8:  HRAS overexpression effect on MCF10A anchorage-independent growth. The 
figure shows the relative number of dead cells after 14 days of culture on coated and uncoated plates.  
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3.2.4. Effect of HRAS overexpression in transduced MCF10A with different TP53 
variants on encourage cell tumorigenicity 
 
MCF10A cells are immortalize normal mammary epithelial cells (Soule et al., 1990). They 
grow as mammosphers, plorized, and glandular structure in vitro. Oncogenes 
overexpression and/or tumor suppresser inactivation leads to the disruption of this normal 
growth pattern. To demonstrate the effect of our manipulation on MCF10A normal growth 
pattern and to better characterize the acquired over growth phenotype that we observed but 
could not very well show in different assays because the cells form clumps, we did 3D 
Matrigel culture assay. As shown in Figure 3.9, the different combinations between 
different TP53 variants had different effects on cell proliferation rate as shown by the size 
of the clumps form and on the invasive pattern of the cells as seen by more cells trying to 
migrate away from these clumps. Compared to the MCF10A parental cells that formed 
normal organized mammoshpers with small size, MCF10A cells without HRAS 
overexpression and TP53, TP53 KO or TP53 R175H formed bigger mammoshpers, the 
biggest ones were the ones formed by TP53 R175H cells. Of note, R175H mutation was 
also enough to a little bit disrupt the normal mammaospher formation towards a more 
invasive one.  Upon HRAS overexpression all clones formed very big cellular clumps 
indicating that HRAS increases cell proliferation in all our cell types. In comparison to each 
other, TP53 R175H cells clumps were the biggest followed by TP53 KO cells and then 
TP53 Wtres cells. In addition, to variable cell clump size, the invasive appearance of the 
clumps was also different with the most invasive growth was observed in TP53 R175H 
cells followed by TP53 KO cells and then TP53 Wtres cells. Altogether, these results 
indicate that HRAS overexpression differentially affects the growth rate and invasiveness 
of cells expressing different TP53 variations.    
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Cell ability to grow independent of extracellular matrix and solid surface is one of cancer 
hallmarks (Hanahan & Weinberg, 2011). Soft agar assay is a widespread used technique 
for in vitro tumorigenic capacity evaluation (Borowicz et al., 2014). To study the effect of 
HRAS overexpression on the tumorigenicty of the different TP53 cells and to verify our eye 
observation about the growth pattern of these cells, that was prevented by technical 
difficulties related to clump formation in 2D culture setup, we did soft agar assay. As shown 
in Figure 3.10, in all non HRAS transformed cell, cells failed to form any colonies with the 
exception of TP53 R175H cells. In HRAS transformed cells, all clones formed colonies of 
different sizes with the biggest formed by TP53 R175H cells followed by TP53 KO and 
finally TP53 Wtres cells. Our results here prove that transformation with HRAS G12V 
affects cell proliferation and tumorigenicty in a different manner and that combination 
between TP53 R175H and HRAS overexpression has the strongest effect on these 
phenotypes.  
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Figure 3.9: Matrigel 3D assay. Representative images at 10X shown the 
colonies organization of the MCF10A transduced clones with and without 
HRAS overexpression. The colonies formation was monitored for 6 days. 
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Figure 3.10: Soft agar assay. Representative images at 10X shown the colonies shape, size and 
migration of the MCF10A transduced clones with and without HRAS overexpression. The colonies 
formation was monitored for 16 days. 
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3.2.5. Effect of HRAS overexpression on the expression of genes related to different 
cancer phenotypes in cells harboring different TP53 variants  
 
To test wither the phenotype we observed in the cells are related to the common gene 
expression pattern induced by HRAS, we did real time PCR to test the expression of genes 
related to different cancer cell phenotypes including cell cycle and cell proliferation (p21, 
CyclinB1), metabolism (IDH1, GLUT1), EMT (Snail1, Slug, Twist1, Cyr61, Wnt5A) and 
cell survival (Bcl2, Bax). As shown in Figure 3.11, HRAS overexpression affected 
different genes in different ways in different cells. For example, in cell proliferation-
related genes, p21 was affected more in TP53 R175H cells compared to other cell lines, 
while CyclinB1 was affected more in TP53 KO cells (Figure 3.11 A). In genes related to 
glucose uptake and metabolism, HRAS overexpression induced GLUT1 expression in 
TP53 KO cells compare to other cell lines. Of note, TP53 R175H was enough to induce 
GLUT1 expression with no difference with HRAS overexpression (Figure 3.11 B). 
Regarding IDH1, while HRAS overexpression led to downregulation of IDH1 in TP53 KO 
cells, it significantly induced it in TP53 R175H cells (Figure 3.11 B). For EMT related 
marker genes, Snail1 was the most affected. It was induced by HRAS in all cell lines but 
the highest expression was observed in TP53 R175H cells. For Slug and Twist1, which are 
also like Snail1 target the epithelial marker e-cadherin and lower it, are not significantly 
affected in all cell lines. Interestingly, in TP53 KO cells the EMT markers Wnt5A and 
Cyr61 were reduced (Figure 3.11 C 1 and 2). For cell death and survival genes Bcl2 was 
induced in all cells but most in TP53 R175H on the other hand Bax was affected mainly 
in TP53 KO cells and to a lesser extent in TP53 Wtres cells, while almost not affected in 
TP53 R15H cells (Figure 3.11 D). In conclusion, HRAS overexpression affected the 
expression of genes related to different oncogenic pathways in a differential manner.   
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Figure 3.11: Genes expression related to different cancer phenotypes levels in transduced MCF10A cells.  
Real time PCR results showing the relative expression level of: (A) p21, CyclinB1, (B) IDH1, GLUT1, (C.1) 
Slug, Snail1, (C.2) Twist1, Cyr61, Wnt5A, and (D) Bcl2, Bax, relative to the house keeping gene UBC. All gene 
expression folds were calculated relative to the expression level in parental cells. Bars indicate the standard 
deviation of the mean of three different biological replicates. The statistical significance of the results was 
determined by measuring the p value. (** means that p-value>0.05 and * means that p-value <0.05). 
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Chapter 4  
 
 
4. Discussion  
 
Identification and understating of cancer transformation is a key stone in cancer biology. In 
the heart of cancer transformation is the interaction between tumor suppressor genes and 
oncogenes (Hanahan & Weinberg, 2011; L. D. Wood et al., 2007). Different studies described 
that the combination between RAS oncogenic activation and p53 inactivation occurs 
recurrently in many cancer types (Solomon et al., 2010; Zhang et al., 2013). RAS is in the 
center of upstream and downstream different signaling pathways that control various cellular 
functions in normal and cancer cells (Maertens & Cichowski, 2014; Myers et al., 2016). In 
breast cancer, different RAS family members , including HRAS, are involved in breast 
epithelia cells signaling pathways like P13K- AKT and RAF-MEK-ERK (Myers et al., 2016; 
Saini et al., 2013). HRAS plays a critical role in RAS-RAF-ERK signaling pathway, which is 
induced in different tumor types such as head, neck, skin and breast (Hobbs et al., 2016; 
McCubrey et al., 2007). p53 is a transcription factor that has different tumor suppressive 
functions in different types of cancer including breast cancer. p53 function is lost in most types 
of cancer, either by being deleted on the genomic level or by inactivating mutations (Walerych 
et al., 2012). Moreover, different p53 mutations not only inactivate p53 but can also lead to 
gain of oncogenic functions (Oren & Rotter, 2010).  Oncogenic constitutively active HRAS 
(HRAS G12V) was shown to negatively regulate p53 tumor suppressive function (Ries et al., 
2000). 
As our preliminary data (not shown) suggests that different TP53 variants have led to 
differential gene expression. We aimed to test the HRAS G12V transformation effect on breast 
cancer related phenotypes on MCF10A cells harboring different TP53 variants in vitro. We 
stably transduced different variants of TP53 into the TP53 KO background to ectopically 
express wild-type and mutant versions of p53. We specifically used the p53 null background 
to overexpress mutant forms of the protein to circumvent dominant-negative effects that might 
occur in a Wt p53 background(Freed-Pastor & Prives, 2012). Using the MCF10A parental 
cells as additional controls we are thus able to distinguish dominant-negative from true gain-
of-function activities of the different variants.  
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First, we validated the successful generation of our model. We found that all our cell lines 
expressed HRAS to the same extent except for cells expressing TP53 R175H, which showed a 
higher HRAS expression compared to other cells. This is an expected result since it was 
reported that p53 R175H  increases HRAS expression through reduction of HRAS inhibitor 
BTG2 (Solomon et al., 2012). In fact, in order to show the expression of exogenous HRAS 
we should have used primers specific for G12V RAS. After measuring HRAS expression, we 
measured p53 expression using Western blot analysis. As expected the TP53 KO cells showed 
no p53 expression at all. The TP53 Wtres cells showed a low p53 expression compared to 
TP53 R175H cells. This variable expression pattern can be explained by the fact that Wt p53 
is continually degraded by its E3 ubiquitin ligase MDM2. On the other hand, it is well 
documented that some p53 mutant variants are stabilized by escaping this post-translational 
regulation mechanism and accumulate in the cell(D. P. Liu et al., 2010; Shetzer, Molchadsky, 
& Rotter, 2016). 
To study the effect of p53-HRAS combination on cancer cell hallmarks, we did different 
cancer transformation related functional assays. In concordance with our findings, different 
studies proved that HRAS overexpression enhances cell proliferation. For example, fibroblast 
cells with HRAS G12V in combination with p27KO exhibited higher proliferation and grew at 
high rate in an anchorage independent manner(Pellizzari et al., 2016). These fibroblasts 
produced tumors when were injected subcutaneously in nude mice (Pellizzari et al., 2016). In 
a further study, MCF10A cells with HRAS overexpression in combinations with wild-type p53 
showed increased cell proliferation (Geyer et al., 2018). In our study, we did different cell 
proliferation assays on our different clones. Both direct and indirect cell proliferation assays 
did not give us reliable results and did not match with our eye observations. This was due to 
the fact that HRAS transformed cells form clumps that did not strongly adhere to cell culture 
surfaces and thus a big portion of the cells was washed away during the different proliferation 
assays. In future studies, we will try to overcome this technical obstacle by culturing the cells 
on either polylysine or gelatin coated cell culture plates.  In agreement with our eye 
observations, it was clear from Matrigrl and soft agar assays that HRAS clones has higher 
proliferative index compared to non-transformed cells. Moreover, from the size of soft agar 
colonies and mammosphers generated by the cells in Matrigel assay, it was obvious that TP53 
R175H cells have the highest proliferation rate. This is similar to what a previous study has 
described. It showed that breast cancer cells with TP53 R175H mutation gain oncogenic 
phenotypes including higher proliferation rates (Rieber & Strasberg Rieber, 2009). On the 
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molecular level, we tested some proliferation related genes and we found that HRAS 
overexpression lowered p21 more in TP53 R175H cells compared to other cell lines. Indeed, 
this result is similar to previous results that showed that TP53 R175H lowers the expression 
of p21 expression level in breast cancer (Rieber & Strasberg Rieber, 2009). In cyclinB1 gene 
case, CyclinB1 was increased more in TP53 KO cells, which expected because p53 is an 
important regulator of cell cycle and prevents the transition between G2 and M phases by 
inhibition of cyclin B1 expression (Hoffmann et al., 2011).  
Another phenotype that changes with cell transformation is cell metabolism (Hanahan & 
Weinberg, 2011). Related to this phenotype, we tested the expression of two cell metabolism 
related-genes GLUT1 and IDH1. GLUTI is the most widely expressed gene related to glucose 
uptake (I. S. Wood & Trayhurn, 2003). In breast cancer it was shown that GLUT1 knockdown 
correlates with low cancer invasiveness phenotypes including lower glucose uptake(Oh, Kim, 
Nam, & Shin, 2017). Regarding IDH1, IDH1gene encodes isocitrate dehydrogenase 1 
enzyme, which is a metabolic enzyme in the Krebs cycle that convert isocitrate to α-
ketoglutarate (α-KG) by using NAD(P)+. IDH1 was found to be mutated in different cancer 
types including  myeloid leukemia (AML), colon cancer , prostate cancer , lung cancer  (B. 
Jiang et al., 2018) and breast cancer (Fathi et al., 2014; W. S. Liu et al., 2018). The mutated 
IDH1 converts α-KG to 2-hydroxyglutarate (2-HG) and that take place of isocitrate 
decarboxylation normal process. This results in 2-HG accumulation, which leads to cancer 
transformation through affecting histone methylation, DNA methylation and other cell events 
(Fathi et al., 2014). We noticed that HRAS overexpression raises GLUTI in both TP53 KO and 
TP53 R175H cells. Whereas in Wtres cells this gene was downregulated when HRAS 
overexpressed. Which is expected because cancer transformation leads to more glycolytic 
dependent cell growth which ensures a higher glucose demand which is supplemented in 
cancer cells in part by increasing GLUT1 expression (Oh et al., 2017; I. S. Wood & Trayhurn, 
2003).In support of our findings, a previous study described that HRAS overexpression leads 
to GLUT1 upregulation by induction of H1F-1(Chen, Pore, Behrooz, Ismail-Beigi, & Maity, 
2001). Also, another study showed that wild-type p53 downregulates GLUT1 expression level 
, while mutated p53 led to increase of GLUT1 (Schwartzenberg-Bar-Yoseph, Armoni, & 
Karnieli, 2004). In comparison to GLUT1, we found that IDH1 expression is was drastically 
lowered in TP53 KO cells which goes along with a more glycolytic growth phenotype. 
Interestingly and unexpectedly, HRAS G12V increased the expression of IDH1 in TP53 
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R175H cells, which ensures the essence of future investigations to try to understand how 
R175H mutation affects IDH1 expression in breast cancer.   
It is well established that cancer cell migration ability and EMT are associated with their 
metastatic potential. EMT and cell migration enable cancer cells to invade blood capillaries , 
circulate and survive in blood , integrate within secondary tissue and form colonies (Hanahan 
& Weinberg, 2011). In this study, we also tested the migratory capacity of our cells using 
wound healing assay. One more time, this assay did not show reliable results too, for the same 
difficulties we faced in cell proliferation assays as described above. However, luckily, in 
Matrigel assay, we were able to confirm our eye observations that indicated that HRAS 
transformation leads to a more migratory and invasive phenotype and that the strongest 
phenotype was clear in R175H cells. In addition, it was shown that TP53 R175H mutation 
induces migration and invasion when co-expressed with constitutively active HRAS in vivo 
and in vitro (D. Jiang et al., 2015). These findings meet with previous study results that showed 
that induction of HRS G12V increases MCF10A cell migration and invasion (Koh et al., 2016; 
Vuoriluoto et al., 2011), and that R175H mutation correlates with higher invasive phenotype 
(Kogan-Sakin et al., 2011). 
p53 contributes to controlling different gene activity that are related to EMT, invasion and 
migration like Slug, Snail and Twist (Muller, Vousden, & Norman, 2011). Also, previous 
research demonstrated that oncogenic RAS activates EMT, induces migration and invasion by 
altering specific genes like, Twist (He et al., 2015) Snail (Horiguchi et al., 2009) Slug 
(Lamouille, Xu, & Derynck, 2014). In order to explain the invasiveness phenotypes on the 
molecular level, we tested different genes were shown to be affected by p53 and HRAS and 
related to cell migration, invasion and EMT. For this purpose, we tested the expression of 
Slug, Snail, Twist1, Wnt5A and Cyr61, which were shown to play very important roles in 
breast cancer progression (Fernandez-Cobo, Zammarchi, Mandeli, Holland, & Pogo, 2007; 
Huang, Lan, Lorusso, Duffey, & Ruegg, 2017; Vuoriluoto et al., 2011; Wang et al., 2016). 
Our results demonstrate that TP53 variants showed differential expression of these markers 
and this can explain the differential migratory and invasiveness phenotype that were shown in 
Matrigel assay. Snail1 was the most affected and the highest expression was observed in TP53 
R175H cells. While, Slug and Twist1 were not significantly affected in all cell lines, while 
remarkably, Wnt5A and Cyr61 were reduced in TP53 KO cells. Altogether, these results 
indicate that different p53 variants can induce the same invasive phenotypes but still by 
utilizing different gene repertoire. 
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Normal epithelial cells require adhesion to the extracellular matrix (ECM) and interaction with 
integrins to receive growth signals, proliferate and survive. When normal epithelial cells 
detached from ECM, they become unconnected to their environment and ECM depletion-
dependent programmed cell death (anoikis) is induced (Kang & Krauss, 1996). Anchorage 
independent growth is an important hallmark of cancer transformation (Hanahan & Weinberg, 
2011). Therefore, it reflects the tumorigenic potential and the aggressiveness of the cancer 
cells (Mori et al., 2009; Wise et al., 2016).  In this study, soft agar assay showed that HRAS 
overexpression induces colony formation in comparison to MCF10A without HRAS 
overexpression. Moreover, we noticed that R175H mutation alone was sufficient to form small 
colonies.  Previous studies demonstrated that that mutated p53 increases breast cancer cells 
survival and resistance to anoikis (Lim, Vidnovic, Ellisen, & Leong, 2009; Tan et al., 2015), 
while another study described that wild-type p53 increases normal mammary epithelial cells 
sensitivity to anoikis (Lim et al., 2009; Tan et al., 2015). Different studies mentioned that 
HRAS overexpression increases the potential for EMT, survival and cancer transformation 
(Datta et al., 2007; Geyer et al., 2018; Solomon et al., 2010).  TP53 KO and TP53 R175H in 
combination with HRAS G12V induced cancer related gene signature that is related to cell 
survival and formed tumors when injected to mice (Buganim et al., 2010). Because survival 
is controlled by the balance between apoptotic and anti-apoptotic genes, we tested the 
expression of the pro-apoptotic gene Bax and the anti-apoptotic gene BCL2 (Chipuk et al., 
2004). It was shown the accumulation of p53 in the cell lead to induce Bax (Chipuk et al., 
2004) and that BCL2 is downregulated in the presence of wild-type p53 (Nakazawa, 
Dashzeveg, & Yoshida, 2014; Ryan et al., 1994). Also, HRAS overexpression was shown to 
alter  the levels of BCL2 (Kinoshita, Yokota, Arai, & Miyajima, 1995) and Bax (Figueiredo 
et al., 2012). Our analysis showed that Bax expression went down in all cells with HRAS 
overexpression, except in TP53 R175H cells where Bax levels were enhanced by HRAS. On 
the other hand, BCL2 increased in all cells with HRAS overexpression and this in concordance 
with soft agar assay results.  
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5. Conclusion and future outlook  
 
In this project, we were able to generate a proof of concept model that can be copied and 
extended to different other mutational combination models. These models can be employed 
to study common as well as model-specific mutations, find shared biomarkers and therapeutic 
targets for the diagnosis and treatment of breast cancer. The potential of this model is 
witnessed by our findings that clearly showed that although cancer cells share common 
phenotypes, these phenotypes are mediated by different gene expression pattern. Of course 
further analysis is needed in order to fully understand some of cell behaviour and the gene 
expression pattern related to them including in vivo studies.   
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  ثديية طبيعيةخلايا  الىنات معدلة رطاني الناتج من تأثير ادخال جيدراسة التحول الس
 
 اعداد : نورالدين يوسف موسى طردي 
 
 اشراف : الدكتور زيدون صلاح 
 الملخص
 
  ، ديالممكن ان تحدث في سرطان الثللتحول السرطاني التي من  خلوية انشاء نماذجبفي هذا البحث  قمنا
   خلال ادخال جين من SARH )desserpxerevo(الى خلايا ثديية طبيعية تحتوي على نسخ جينية 
  جينمختلفة من   35PT .
مستوى  ائها علىاختبرنا الاختلافات الناتجة من التحول السرطاني في النماذج التي قمنا بانش ،بعد ذلك 
 ويةالخل تميزت تلك النماذجو  .التعبير الجيني لبعض الجينات المتعلقة بتلك الصفاتالصفات الشكلية و 
وت الخلوي مقاومتها للم، و  قدرتها على التنقلو  زيادة قابليتها للانتشاربتغير واضح في صفاتها الشكلية و 
تحول ال على تحريضالفي ا مهم  ا لاجتماع اكثر من طفرة جينية توضح هذه الدراسة دور  و . المبرمج 
د قوالذي بدوره  لسرطان الثدي يسرطانالتحول ال. وإجمالا ، نجحنا في توليد نماذج لدراسة يالسرطان
توظيفها في تحسين ل السرطاني لها ، و يساعد في فهم سلوك خلايا سرطان الثدي وكيفية حدوث التحو 
  التشخيص والعلاج. طرق الكشف و 
 
 
 
